• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More or Call (407) 374-6986

Sunday 12/9/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Cannabics Pharmaceuticals

  • 11:55 AM

    TEL-AVIV, Israel, Nov. 28, 2017, CNBX, /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) announced today that it has received a new research license from the Israeli Ministry of Health for the Characterization of anti-tumor activity of cannabinoids. The new license will enable the company to continue our vision of developing an ecosystem for creation of diagnostic tools and bringing to the market diagnostic services for cancer patients who are medicated with cannabis. Our forward looking plan encompasses a synergy between HTS (High Throughput

    Read more
  • 1:37 PM

    TEL-AVIV, Israel, August 28, 2017, CNBX, /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) (OTCQB: CNBX) today announced it received a very positive preliminary international patentability report from the PCT authorities regarding patent application PCT/IL2016/050471 finding all claims innovative and inventive. This PCT report is a major step in the progress of the patent application which is now being launched into several major countries and territories. The company is securing its achievements through a very active and expanding patent portfolio. Other 2nd. Generation patent

    Read more
  • 3:05 PM

    TEL AVIV, Israel, July 24, 2017, CNBX, /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTC-QB: CNBX) today announced it has established a Genetic lab that will develop diagnostic tools based on human genome, tumor genetics and cannabinoids. The company recruited Dr. Moran Grinberg to serve as its VP of R&D and to lead the Genetic research. Moran has a PhD in Virology and MSc in clinical pharmacology with vast experience in conceptualizing and executing pharmacological research. Dr. Eyal Ballan, Co-founder and CTO, said: “Our mission is to commercialize

    Read more
  • 4:22 PM

    TEL AVIV, Israel, April 3, 2017, CNBX, /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) is pleased to announce that it received the final report of the research held in the Technion Israel Institute of Technology, in which the antitumor activity of cannabinoids was reflected in several types of cancer (breast, ovarian, colon, pancreatic, gastric, glioblastoma). The results which were obtained, using High Throughput Screening technology (HTS), clearly indicate that the company’s cannabinoid compounds caused apoptosis (programed cancer cell death) in all

    Read more
  • 3:42 PM

    PV Enterprises International (PublicWire.com Press Release) — FORT LAUDERDALE, Fla., December 20th, 2013–PV Enterprises International, Inc. (OTC: PVEC, the “Company”), a global shipping management company spinning into specialty cruise ecotourism, is pleased to provide a following corporate update to its shareholders and the investment community. This release includes information about the company’s recent ticker symbol change. In alignment with the company’s revised corporate objectives, PV Enterprises Int’l has enacted several important transformative changes to its corporate structure that reflect the

    Read more
Public Wire Banner